ADU-1805
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a Kd value of 11.0 × 10-9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
ADU-1805 binds to hSIRPαV1 with a Kd value of 11.0 × 10-9 M, and exhibits binding properties similar to those of the parental and chimeric hSIRPα.40A antibody variants[1].
ADU-1805 potently binds to primary monocytes and neutrophils, while exhibits extremely weak binding to lymphocytes[1].
ADU-1805 (0.67-66.7 nM; 2 h) promotes Rituximab (HY-P9913)-mediated phagocytosis of Raji Burkitt's lymphoma cells by peripheral blood-derived macrophages in a concentration-dependent manner[1].
ADU-1805 (0.067-66.7 nM; 2 h) enhances Rituximab-mediated trogocytosis of primary neutrophils against BJAB Burkitt's lymphoma cells in a concentration-dependent manner[1].
ADU-1805 does not bind to primary red blood cells or platelets, nor does it induce hemagglutination of red blood cells[1].
ADU-1805 (5 days) neither inhibits T cell activation nor reduces T cell counts in allogeneic mixed lymphocyte reactions[1].
ADU-1805 (100 μg/mL; 3 days) does not inhibit SEB-induced T cell activation and proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Macaca fascicularis (5-7 years old; male and female; purpose-bred from Asia)[1]
-
Dosage:0.3 mg/kg; 3 mg/kg; 30 mg/kg
-
Administration:i.v.; single 15-minute infusion
-
Result:Showed dose-proportional exposure increase for 3 mg/kg and 30 mg/kg dose levels, with an estimated half-life of 1.86-6.41 days.
Demonstrated no test-article related changes in clinical observations, body weight, food consumption, neurologic or cardiovascular parameters, serum chemistry, hematology, coagulation, organ weights, or histopathology.
Maintained stable hemoglobin levels across all dose groups, with no signs of acute anemia or thrombocytopenia.
SIRPa/CD172a
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ADU-1805 Related Classifications
HY-P992176 Related Classifications
Powered by Bioz